IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is among the greatest healthcare shares with the very best upside. Residents JMP analyst Silvan Tuerkcan launched a score replace for IDEAYA Biosciences, Inc. (NASDAQ:IDYA) on October 13, sustaining a Purchase score for the inventory with a value goal of $45.
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) additionally acquired a bullish score from J.P. Morgan analyst Anupam Rama on September 23, who assigned the inventory a Purchase score with a $74 value goal.
The analyst based mostly the score on a number of promising developments related to the corporate’s lead asset, darovasertib, stating that IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is anticipated to launch notable updates on darovasertib in a number of remedy settings. That is anticipated to help vital worth creation.
Darovasertib is a small molecule for sufferers with uveal melanoma, which is a uncommon kind of eye most cancers with appreciable unmet medical want.
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) develops oncology-focused precision drugs, specializing in focused therapeutics for sufferers chosen utilizing molecular diagnostics. The corporate’s product candidate is IDE196, a protein kinase C inhibitor that targets genetically outlined cancers with GNAQ or GNA11 gene mutations.
Whereas we acknowledge the potential of IDYA as an funding, we imagine sure AI shares supply larger upside potential and carry much less draw back threat. In the event you’re on the lookout for an especially undervalued AI inventory that additionally stands to learn considerably from Trump-era tariffs and the onshoring development, see our free report on the greatest short-term AI inventory.
READ NEXT: 30 Shares That Ought to Double in 3 Years and 11 Hidden AI Shares to Purchase Proper Now.
Disclosure: None. This text is initially printed at Insider Monkey.
